Skip to main
ORIC
ORIC logo

Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

Oric Pharmaceuticals (ORIC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 42%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

ORIC Pharmaceuticals Inc. is positioned for a promising future, with its focus on innovative therapies aimed at overcoming resistance mechanisms in cancer, specifically through its lead product candidate, ORIC-944. The company's recent updates on clinical data and positive feedback from key opinion leaders highlight the scientific rationale backing the development of its product candidates, suggesting a favorable outlook as the company navigates a catalyst-rich period over the next 18 months. Furthermore, ORIC has successfully extended its cash runway into 2027, providing a solid financial foundation to support its ongoing research and development initiatives.

Bears say

ORIC Pharmaceuticals is projecting a significant net loss of $2.22 per share for the full year 2025, which raises concerns about the company's financial stability. The potential inability to advance key pipeline candidates ORIC-114 and ORIC-944, coupled with risks associated with negative clinical outcomes and regulatory delays, poses substantial challenges to the company's growth prospects. Additionally, factors such as slower market uptake, lower-than-expected peak sales, and long-term dilution risk further exacerbate the negative outlook for ORIC Pharmaceuticals's stock.

Oric Pharmaceuticals (ORIC) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 42% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oric Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oric Pharmaceuticals (ORIC) Forecast

Analysts have given Oric Pharmaceuticals (ORIC) a Buy based on their latest research and market trends.

According to 12 analysts, Oric Pharmaceuticals (ORIC) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oric Pharmaceuticals (ORIC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.